MiNK Therapeutics, Inc. - INKT STOCK NEWS

MiNK Therapeutics has unveiled clinical data on their allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, in a severe ARDS case at the ATS Annual Meeting. The subject, a 26-year-old post-renal transplant immunocompromised individual who developed severe hypoxemic respiratory failure due to COVID-19, was treated with a single dose of agenT-797. Significant clinical improvements included reduced inflammatory cytokines and successful extubation by day 37. The patient was discharged by day 60 and resumed normal activities within six months. These findings align with Phase 1 trial data, supporting the potential of agenT-797 in treating severe respiratory conditions in immune-compromised patients.

MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2024 results, highlighting significant progress in its invariant natural killer T (iNKT) cell therapy programs. Key developments include a $5.8 million private placement financing at a 25% premium, which will expedite the clinical entry of MiNK-215 for solid tumors. Clinical trials for agenT-797 in gastroesophageal cancers are ongoing, with initial results expected later in 2024. Preclinical data showcased MiNK-215's potential in treating MSS colorectal cancer liver metastases. Financially, MiNK ended the quarter with $5.8 million in cash, reduced net losses to $3.8 million (down from $5.7 million in Q1 2023), and decreased operating expenses.

MiNK Therapeutics, Inc. announced a $5.8 million private placement financing to advance the clinical trials of MiNK-215, their leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein in solid tumors. The financing includes a 25% premium, selling 4,640,000 shares of common stock at $1.25 per share. The funding will help accelerate the clinical development of MiNK-215, planned to enter the clinic in early 2025. Additionally, Katie Chudnovsky has been appointed as a Board Observer, bringing extensive experience in the medical research field.

MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its first quarter 2024 financial results on May 14, 2024. The company is focused on developing iNKT cell therapies for cancer and immune diseases. An executive conference call and webcast will follow to discuss the results and provide a corporate update.

MiNK-215, a novel cellular therapy developed by MiNK Therapeutics, has shown promising results in combating colorectal cancer liver metastases. The therapy, presented at AACR, demonstrated significant anti-tumor activity through various mechanisms, offering hope to patients with treatment-resistant cancer. MiNK-215's collaboration potential with other immunotherapies like botensilimab and balstilimab highlights its versatility and effectiveness in enhancing the anti-tumor response.

MiNK Therapeutics, Inc. (INKT) announced significant advancements in allogeneic iNKT cell therapies for cancer and immune-mediated diseases. Key highlights include the launch of a Phase 2 trial in gastroesophageal cancers, positive clinical data in solid tumors and ARDS, collaboration with Immunoscape, and financial results for Q4 and full-year 2023.

MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its fourth quarter and year-end 2023 financial results on March 21, 2024. The company focuses on developing iNKT cell therapies for cancer and immune-mediated diseases.

MiNK-215, an IL-15 armored FAP-targeting CAR-iNKT cell therapy, showed promising results in eradicating tumor cells in human organoid MSS colorectal cancer liver metastases models. The therapy enhanced tumor killing by T cells, depleted immune suppressive cells, and increased CD8+ T cell infiltration, potentially improving outcomes for patients with liver metastases.

MiNK Therapeutics, Inc. (INKT) announces the initiation of a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer at Memorial Sloan Kettering Cancer Center. The study aims to address the treatment challenges faced by ~70% of Gastroesophageal Cancer (GEC) patients. The trial involves a novel combination of Allogeneic Cell Therapy with BOT/BAL and aims to evaluate the safety and efficacy of agenT-797 in combination with botensilimab, balstilimab, ramucirumab, and paclitaxel for patients with advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma.